指南与共识复苏、休克与脓毒症心脑血管急症

成人心脏骤停核心结局集(COSCA):国际复苏联络委员会咨询声明

COSCA (Core Outcome Set for Cardiac Arrest) in Adults: An Advisory Statement From the International Liaison Committee on Resuscitation.
PubMed 文献 · Resuscitation · 2018-04-26
一句话结论国际复苏联络委员会(ILCOR)推荐:成人心脏骤停有效性试验应报告生存、神经功能与健康相关生活质量三项核心结局。

心脏骤停有效性试验传统上以生存为主要结局,试验间结局报告不一致限制了荟萃分析。COSCA 倡议由患者、伴侣、临床医生、科研人员与 ILCOR 合作,通过系统综述、心脏骤停幸存者定性访谈、德尔菲过程及国际顾问小组辩论达成共识,制定成人心脏骤停有效性试验核心结局集。共识推荐报告生存、神经功能与健康相关生活质量三项核心域。生存与神经功能应以出院时、30天或两者兼有的生存状态与改良Rankin量表评分报告;健康相关生活质量应在90天及心脏骤停后至1年期间定期测量,资源允许时使用 Health Utilities Index version 3、Short-Form 36-Item Health Survey 和 EuroQol 5D-5L 中至少一种工具。

要点

  • COSCA 核心结局集适用于成人心脏骤停大型随机临床有效性试验,而非试点或效力研究。
  • 核心结局集包括三项核心域:生存、神经功能、健康相关生活质量。
  • 生存与神经功能应以出院时、30天或两者兼有的生存状态与改良Rankin量表评分报告。
  • 健康相关生活质量应在90天及心脏骤停后至1年期间定期测量(资源允许时)。
  • 健康相关生活质量测量工具为 Health Utilities Index version 3、Short-Form 36-Item Health Survey 和 EuroQol 5D-5L 中至少一种。

适用人群与场景

  • 成人心脏骤停有效性试验(大型随机临床有效性试验,有时称为实用性试验或III/IV期试验)的结局报告,而非试点或效力研究。

研究设计与关键结果

  • COSCA 由患者、伴侣、临床医生、科研人员与国际复苏联络委员会合作,通过系统综述、心脏骤停幸存者定性访谈、德尔菲过程及国际顾问小组辩论达成共识,制定成人心脏骤停有效性试验核心结局集。
  • 共识认为成人心脏骤停有效性研究核心结局集应包括生存、神经功能与健康相关生活质量三项核心域。
  • 生存与神经功能应以出院时、30天或两者兼有的生存状态与改良Rankin量表评分报告。
  • 健康相关生活质量应在90天及心脏骤停后至1年期间定期测量(资源允许时),使用 Health Utilities Index version 3、Short-Form 36-Item Health Survey 和 EuroQol 5D-5L 中至少一种工具。

证据类型、等级与局限

  • 证据类型:国际复苏联络委员会咨询声明,基于系统综述、定性访谈、德尔菲过程及国际顾问小组共识。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,成人心脏骤停有效性试验应统一报告生存、神经功能与健康相关生活质量三项核心结局,以减少试验间结局报告不一致、便于荟萃分析合并结果。
  • 作者认为,生存与神经功能应在出院时、30天或两者兼有报告,健康相关生活质量应在90天及至1年期间定期测量(资源允许时)。

指南或共识出处

  • COSCA (Core Outcome Set for Cardiac Arrest) in Adults: An Advisory Statement From the International Liaison Committee on Resuscitation,国际复苏联络委员会(International Liaison Committee on Resuscitation),2018年。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Cardiac arrest effectiveness trials have traditionally reported outcomes that focus on survival. A lack of consistency in outcome reporting between trials limits the opportunities to pool results for meta-analysis. The COSCA initiative (Core Outcome Set for Cardiac Arrest), a partnership between patients, their partners, clinicians, research scientists, and the International Liaison Committee on Resuscitation, sought to develop a consensus core outcome set for cardiac arrest for effectiveness trials. Core outcome sets are primarily intended for large, randomised clinical effectiveness trials (sometimes referred to as pragmatic trials or phase III/IV trials) rather than for pilot or efficacy studies. A systematic review of the literature combined with qualitative interviews among cardiac arrest survivors was used to generate a list of potential outcome domains. This list was prioritised through a Delphi process, which involved clinicians, patients, and their relatives/partners. An international advisory panel narrowed these down to 3 core domains by debate that led to consensus. The writing group refined recommendations for when these outcomes should be measured and further characterised relevant measurement tools. Consensus emerged that a core outcome set for reporting on effectiveness studies of cardiac arrest (COSCA) in adults should include survival, neurological function, and health-related quality of life. This should be reported as survival status and modified Rankin scale score at hospital discharge, at 30 days, or both. Health-related quality of life should be measured with ≥1 tools from Health Utilities Index version 3, Short-Form 36-Item Health Survey, and EuroQol 5D-5L at 90 days and at periodic intervals up to 1 year after cardiac arrest, if resources allow. © 2018 European Resuscitation Council and American Heart Association, Inc. Published by Elsevier B.V. All rights reserved.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Haywood K, Whitehead L, Nadkarni VM, et al. COSCA (Core Outcome Set for Cardiac Arrest) in Adults: An Advisory Statement From the International Liaison Committee on Resuscitation. Resuscitation. 2018. PMID: 29706235. doi:10.1016/j.resuscitation.2018.03.022

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。